Cost-effectiveness of viral hepatitis B & C treatment

Best Practice and Research: Clinical Gastroenterology

Volumn 27, Issue 6, 2013, Pages 973-985

  Toy, Mehlika ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cost effectiveness; Hepatitis B; Hepatitis C; Treatment

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; BOCEPREVIR; ENTECAVIR; LAMIVUDINE; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; TELBIVUDINE; TENOFOVIR;

ANTIVIRAL THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DRUG COST; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION; LIVER CIRRHOSIS; MONOTHERAPY; NONHUMAN; QUALITY OF LIFE; TREATMENT RESPONSE;

EID: 84887146806     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2013.08.020     Document Type: Review

References (88)

1. D. Lavanchy Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepat 11 2 2004 97 107 (Pubitemid 38365759)
2. D. Lavanchy Evolving epidemiology of hepatitis C virus Clin Microbiol Infect 17 2 2011 107 115
3. B.J. McMahon The natural history of chronic hepatitis B virus infection Hepatology 49 5 Suppl. 2009 S45 S55 [Epub 2009/04/29]
4. H.B. El-Serag Epidemiology of viral hepatitis and hepatocellular carcinoma Gastroenterology 142 6 2012 1264 1273 e1 [Epub 2012/04/28]
5. D. Lavanchy Chronic viral hepatitis as a public health issue in the world Best Pract Res 22 6 2008 991 1008
6. C. Cohen, S.D. Holmberg, B.J. McMahon, J.M. Block, C.L. Brosgart, and R.G. Gish Is chronic hepatitis B being undertreated in the United States? J Viral Hepat 18 6 2010 377 383
7. A.C. El Khoury, J. Vietri, and G. Prajapati The burden of untreated hepatitis C virus infection: a US patients' perspective Dig Dis Sci 57 11 2012 2995 3003
8. B.I. Idris, M. Brosa, J.H. Richardus, R. Esteban, S.W. Schalm, and M. Buti Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain Eur J Gastroenterol Hepatol 20 4 2008 320 326 (Pubitemid 351374236)
9. M. Toy, I.K. Veldhuijzen, R.A. de Man, J.H. Richardus, and S.W. Schalm Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B Hepatology 50 3 2009 743 751 [Epub 2009/07/09]
10. S.E. Post, N.K. Sodhi, C.H. Peng, K. Wan, and H.J. Pollack A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective Health Affairs (Project Hope) 30 2 2011 340 348
11. D.B. Rein, J.S. Wittenborn, C.M. Weinbaum, M. Sabin, B.D. Smith, and S.B. Lesesne Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States Dig Liver Dis Off J Italian Soc Gastroenterol Italian Assoc Study Liver 43 1 2011 66 72 [Epub 2010/08/27]
12. I.K. Veldhuijzen, M. Toy, S.J. Hahne, G.A. De Wit, S.W. Schalm, and R.A. de Man Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective Gastroenterology 138 2 2010 522 530 [Epub 2009/11/03]
13. World Health Assembly WHA63.18: viral hepatitis 2010 World Health Organization Geneva, Switzerland
14. D.K. Owens, A. Qaseem, R. Chou, and P. Shekelle High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions Ann Intern Med 154 3 2011 174 180
15. F.A. Sonnenberg, and J.R. Beck Markov models in medical decision making: a practical guide Med Decis Mak An Int J Soc Med Decis Mak 13 4 1993 322 338 [Epub 1993/10/01] (Pubitemid 24013155)
16. EASL clinical practice guidelines: management of chronic hepatitis B virus infection J Hepatol 57 1 2012 167 185 [Epub 2012/03/23]
17. T.T. Chang, R.G. Gish, R. de Man, A. Gadano, J. Sollano, and Y.C. Chao A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B New Eng J Med 354 10 2006 1001 1010 (Pubitemid 43357804)
18. P. Marcellin, E.J. Heathcote, M. Buti, E. Gane, R.A. de Man, and Z. Krastev Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B New Eng J Med 359 23 2008 2442 2455
19. T.T. Chang, C.L. Lai, S. Kew Yoon, S.S. Lee, H.S. Coelho, and F.J. Carrilho Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 51 2 2010 422 430 [Epub 2010/01/06]
20. E.J. Heathcote, P. Marcellin, M. Buti, E. Gane, R.A. De Man, and Z. Krastev Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B Gastroenterology 140 1 2011 132 143
21. A. Snow-Lampart, B. Chappell, M. Curtis, Y. Zhu, F. Myrick, and J. Schawalder No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus Hepatology 53 3 2011 763 773
22. C.L. Lai, D. Shouval, A.S. Lok, T.T. Chang, H. Cheinquer, and Z. Goodman Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B New Eng J Med 354 10 2006 1011 1020 [Epub 2006/03/10] (Pubitemid 43357805)
23. Y.F. Liaw Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update Hepatol Int 6 2012 531 561
24. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
25. V. Rijckborst, M.J. Sonneveld, and H.L. Janssen Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy? Aliment Pharmacol Ther 33 5 2011 501 513
26. H.L. Janssen, M. van Zonneveld, H. Senturk, S. Zeuzem, U.S. Akarca, and Y. Cakaloglu Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 9454 2005 123 129 (Pubitemid 40091801)
27. E.H. Buster, H.J. Flink, Y. Cakaloglu, K. Simon, J. Trojan, and F. Tabak Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b Gastroenterology 135 2 2008 459 467
28. P. Marcellin, G.K. Lau, F. Bonino, P. Farci, S. Hadziyannis, and R. Jin Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B New Eng J Med 351 12 2004 1206 1217 (Pubitemid 39296307)
29. M.F. Yuen, and C.L. Lai Treatment of chronic hepatitis B: evolution over two decades J Gastroenterol Hepatol 26 Suppl. 1 2011 138 143 [Epub 2011/01/14]
30. C.L. Lai, R.N. Chien, N.W. Leung, T.T. Chang, R. Guan, and D.I. Tai A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group New Eng J Med 339 2 1998 61 68 (Pubitemid 28304879)
31. D.N. Moskovitz, C. Osiowy, E. Giles, G. Tomlinson, and E.J. Heathcote Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance J Viral Hepat 12 4 2005 398 404 [Epub 2005/06/30] (Pubitemid 40961480)
32. Y.F. Liaw, E. Gane, N. Leung, S. Zeuzem, Y. Wang, and C.L. Lai 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B Gastroenterology 136 2 2009 486 495 [Epub 2008/11/26]
33. P. Marcellin, T.T. Chang, S.G. Lim, M.J. Tong, W. Sievert, and M.L. Shiffman Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B New Eng J Med 348 9 2003 808 816 [Epub 2003/02/28] (Pubitemid 36245757)
34. Y.S. Lee, D.J. Suh, Y.S. Lim, S.W. Jung, K.M. Kim, and H.C. Lee Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy Hepatology 43 6 2006 1385 1391 [Epub 2006/05/27] (Pubitemid 43980117)
35. P. Marcellin, and T. Asselah Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal J Gastroenterol Hepatol 28 6 2013 912 923
36. D.J. Tenney, R.E. Rose, C.J. Baldick, K.A. Pokornowski, B.J. Eggers, and J. Fang Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy Hepatology 49 5 2009 1503 1514
37. P. Marcellin, E. Gane, M. Buti, N. Afdhal, W. Sievert, and I.M. Jacobson Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study Lancet 381 9865 2013 468 475 [Epub 2012/12/14]
38. EASL clinical practice guidelines: management of hepatitis C virus infection J Hepatol 55 2 2011 245 264
39. M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, and L.B. Seeff An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 4 2012 1433 1444
40. M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 4 2009 1335 1374 [Epub 2009/03/31]
41. M. Omata, T. Kanda, M.L. Yu, O. Yokosuka, S.G. Lim, and W. Jafri APASL consensus statements and management algorithms for hepatitis C virus infection 2012
42. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 9286 2001 958 965 (Pubitemid 32913521)
43. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection New Eng J Med 347 13 2002 975 982
44. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem Boceprevir for previously treated chronic HCV genotype 1 infection New Eng J Med 364 13 2011 1207 1217
45. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection New Eng J Med 364 13 2011 1195 1206 [Epub 2011/04/01]
46. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection New Eng J Med 364 25 2011 2405 2416 [Epub 2011/06/24]
47. I.M. Jacobson, J.M. Pawlotsky, N.H. Afdhal, G.M. Dusheiko, X. Forns, and D.M. Jensen A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C J Viral Hepat 19 Suppl. 2 2012 1 26 [Epub 2012/04/19]
48. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, and T.J. Urban Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 7262 2009 399 401
49. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, and M.L. Abate IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nature Genetics 41 10 2009 1100 1104
50. Y. Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, and N. Sakamoto Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nature Genetics 41 10 2009 1105 1109
51. D.L. Thomas, C.L. Thio, M.P. Martin, Y. Qi, D. Ge, and C. O'Huigin Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 7265 2009 798 801
52. M.R. Gold, J.E. Siegel, L.B. Russell, and M.C. Weinstein Cost-effectiveness in health and medicine 1996 Oxford University Press New York
53. A.S. Detsky, and I.G. Naglie A clinician's guide to cost-effectiveness analysis Ann Intern Med 113 2 1990 147 154 [Epub 1990/07/15] (Pubitemid 20218632)
54. P.J. Neumann, and M.C. Weinstein Legislating against use of cost-effectiveness information New Eng J Med 363 16 2010 1495 1497 [Epub 2010/10/15]
55. W.C. Black The CE plane: a graphic representation of cost-effectiveness Med Decis Mak An Int J Soc Med Decis Mak 10 3 1990 212 214 [Epub 1990/07/01] (Pubitemid 20311440)
56. WHO guide to cost-effectiveness 2003 World Health Organization
57. E. Arnold, Y. Yuan, U. Iloeje, and G. Cook Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B Appl Health Econ Health Policy 6 4 2008 231 246 [Epub 2008/01/01]
58. M. Buti, M. Brosa, M.A. Casado, M. Rueda, and R. Esteban Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B J Hepatol 51 4 2009 640 646 [Epub 2009/07/07]
59. G.L. Colombo, G.B. Gaeta, M. Vigano, and S. Di Matteo A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy Clin Econ Outcomes Res CEOR 3 2011 37 46 [Epub 2011/09/22]
60. A.M. Costa, G. Li, M.E. Nita, and E.S. Araujo Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil Brazilian J Infect Dis Off Publ Brazilian Soc Infect Dis 12 5 2008 368 373 [Epub 2009/02/17]
61. H. Dakin, A. Bentley, and G. Dusheiko Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B Value in Health J Int Soc Pharmacoeconomics Outcomes Res 13 8 2010 922 933 [Epub 2010/09/10]
62. H. Dakin, M. Sherman, S. Fung, C. Fidler, and A. Bentley Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective PharmacoEconomics 29 12 2011 1075 1091
63. F. Hulstaert, C. Schwierz, F. Nevens, N. Thiry, M. Gamil, and I. Colle Should chronic hepatitis B be treated as early as possible? Int J Technol Assess Health Care 29 1 2013 35 41 [Epub 2013/01/10]
64. S. Iannazzo, B. Coco, M.R. Brunetto, F. Rossetti, A. Caputo, and A. Latour Individualized treatment of HBeAg-negative CHB using peg-interferon alfa-2a as first-line and week 12 HBV-DNA/HBsAg stopping rule. A cost-effectiveness analysis Antivir Ther 2013 [Epub 2013/03/15]
65. Y.Y. Lui, K.K. Tsoi, V.W. Wong, J.H. Kao, J.L. Hou, and E.K. Teo Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy Antivir Ther 15 2 2010 145 155 [Epub 2010/04/14]
66. J.Y. Park, J. Heo, T.J. Lee, H.J. Yim, J.E. Yeon, and Y.S. Lim A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options PloS One 8 3 2013 e57900 [Epub 2013/03/29]
67. D.E. Spackman, and D.L. Veenstra A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B PharmacoEconomics 26 11 2008 937 949 [Epub 2008/10/15]
68. M. Toy, F.O. Onder, R. Idilman, G. Kabacam, J.H. Richardus, and M. Bozdayi The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country Eur J Health Econ HEPAC Health Econ Prev Care 13 5 2012 663 676 [Epub 2012/07/21]
69. D.L. Veenstra, D.E. Spackman, A. Di Bisceglie, K.V. Kowdley, and R.G. Gish Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis Aliment Pharmacol Ther 27 12 2008 1240 1252 [Epub 2008/04/01] (Pubitemid 351697278)
70. B. Wu, T. Li, H. Chen, and J. Shen Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis Value in Health J Int Soc Pharmacoeconomics Outcomes Res 13 5 2010 592 600 [Epub 2010/06/22]
71. Y. Yuan, U.H. Iloeje, J. Hay, and S. Saab Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients J Manag Care Pharm JMCP 14 1 2008 21 33 [Epub 2008/02/05] (Pubitemid 351325191)
72. M. Barbieri, M. Drummond, R. Willke, J. Chancellor, B. Jolain, and A. Towse Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability Value in Health J Int Soc Pharmacoeconomics Outcomes Res 8 1 2005 10 23 [Epub 2005/04/22] (Pubitemid 40293637)
73. L. Bernfort, K. Sennfalt, and O. Reichard Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden Scand J Infect Dis 38 6-7 2006 497 505 [Epub 2006/06/27] (Pubitemid 44150788)
74. M. Buti, M. Medina, M.A. Casado, J.B. Wong, L. Fosbrook, and R. Esteban A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C Aliment Pharmacol Ther 17 5 2003 687 694 [Epub 2003/03/19] (Pubitemid 36418893)
75. C. Camma, S. Petta, G. Cabibbo, M. Ruggeri, M. Enea, and R. Bruno Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C J Hepatol 2013 [Epub 2013/05/28]
76. C. Camma, S. Petta, M. Enea, R. Bruno, F. Bronte, and V. Capursi Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C Hepatology 56 3 2012 850 860 [Epub 2012/03/29]
77. K. Chan, M.N. Lai, E.J. Groessl, A.D. Hanchate, J.B. Wong, and J.A. Clark Cost-effectiveness analysis of direct-acting antiviral therapy for treatment-naive patients with chronic hepatitis C genotype 1 infection in the veterans health administration Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2013 [Epub 2013/05/28]
78. E.H. Elbasha, J. Chhatwal, S.A. Ferrante, A.C. El Khoury, and P.A. Laires Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal Appl Health Econ Health Policy 11 1 2013 65 78 [Epub 2013/01/29]
79. S.A. Ferrante, J. Chhatwal, C.A. Brass, A.C. El Khoury, F. Poordad, and J.P. Bronowicki Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study BMC Infect Dis 13 1 2013 190 [Epub 2013/04/30]
80. M.C. Fonseca, G.T. Araujo, and D.V. Araujo Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil Brazilian J Infect Dis Off Publ Brazilian Soc Infect Dis 13 3 2009 191 199 Epub 2010/03/02
81. S. Gerkens, M. Nechelput, L. Annemans, B. Peraux, C. Beguin, and Y. Horsmans A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels Acta Gastro-enterologica Belgica 70 2 2007 177 187 [Epub 2007/08/25] (Pubitemid 47066269)
82. M. Grishchenko, R.D. Grieve, M.J. Sweeting, D. De Angelis, B.J. Thomson, and S.D. Ryder Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice Int J Technol Assess Health Care 25 2 2009 171 180 [Epub 2009/04/01]
83. Y. Iwasaki, H. Tanaka, H. Ikeada, R. Okamoto, Y. Araki, and K. Yabushita Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2 Scand J Gastroenterol 46 1 2011 79 90 [Epub 2010/09/09]
84. W.A. Lin, Y.H. Tarn, and S.L. Tang Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naive Chinese patients with chronic hepatitis C Aliment Pharmacol Ther 24 10 2006 1483 1493 [Epub 2006/11/04]
85. S. Liu, L.E. Cipriano, M. Holodniy, D.K. Owens, and J.D. Goldhaber-Fiebert New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis Ann Intern Med 156 4 2012 279 290 [Epub 2012/02/22]
86. J.A. Salomon, M.C. Weinstein, J.K. Hammitt, and S.J. Goldie Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population JAMA J Am Med Assoc 290 2 2003 228 237 [Epub 2003/07/10] (Pubitemid 37430062)
87. U. Siebert, G. Sroczynski, P. Aidelsburger, S. Rossol, J. Wasem, and M.P. Manns Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines PharmacoEconomics 27 4 2009 341 354 [Epub 2009/06/03]
88. K. Stein, W. Rosenberg, and J. Wong Cost effectiveness of combination therapy for hepatitis C: a decision analytic model Gut 50 2 2002 253 258 [Epub 2002/01/15] (Pubitemid 34087941)